News from Tuesday, April 7, 2026
Articles
Perspectives from IVI’s 7th Annual Methods Summit: Integrating Patient and Caregiver Perspectives into Real-World Value Assessment
(4/7, Katie McCool, The Evidence Base) reports “...Laura Pizzi (ISPOR) described how healthcare systems globally are recognizing the need to broaden definitions of value. She outlined ISPOR’s evolving strategic direction, explaining that the organization aims to support ‘a world where healthcare is effective, efficient, affordable and accessible for all.’ According to Pizzi, this shift reflects growing recognition that healthcare outcomes are closely linked to broader societal and economic factors. Pizzi highlighted the emergence of approaches that extend beyond traditional cost-effectiveness analysis to capture wider aspects of health and wellbeing. She emphasized that value cannot be understood solely through clinical or economic measures but must also reflect the environments in which care is delivered...” Full
Press Releases
ISPOR Publishes Recommendations on Valuing Child and Adolescent Health for Economic Evaluations
(4/7, ISPOR Press Release) “Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Good Practices Report providing first-of-its-kind international guidance on quantifying the value of health outcomes in children. The report, ‘Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force,’ was published in the April 2026 issue of Value in Health.” Full
New Study Shows Increasing Value of Real-World Data (RWD) in Clinical Trials
(4/7, Verana Health Press Release) “New research by Tufts Center for the Study of Drug Development (CSDD) documents the growing importance of real-world data (RWD) and real-world evidence (RWE) in clinical trials. The study, ‘The Use of Real-World Data and Evidence in Clinical Trials,’ highlights the increasing value of RWD and RWE in decision-making, trial optimization, commercialization, and real-world efficacy.” Full
Institute for Clinical and Economic Review Releases Draft Evidence Report on Vaccines for Covid-19
(4/7, ICER Press Release) “The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Comirnaty® (Pfizer, BioNTech), Spikevax® (Moderna), mNexspike® (Moderna), and Nuvaxovid® (Sanofi) for the protection against Covid-19, including both the short- and long-term effects of the infection.” Full
Journals
Patient-Reported Outcome Measures for Technology Assessment: A Comparison Between Three-Dimensional Conformal and Intensity-Modulated Radiotherapy in Prostate Cancer
Arantxa Mera, et al.
March 24, 2026, World Journal of Clinical Oncology
World Journal of Clinical Oncology
Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force
Louis S. Matza, et al.
April 2026, Value in Health
‘Most Favored Nation’ Policies And Value-Based Drug Pricing: A European View
Francis Megerlin
April 2026, Health Affairs
Cost-Effectiveness Thresholds Used in the United States versus Most Favored Nations
Hanxuan Yu, et al.
April 3, 2026, Health Affairs Scholar
Comparative Effectiveness and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis
Bin Huang, et al.
April 7, 2026, Advances in Therapy
A Novel Visualization Approach for Network Meta-Analysis: The Plate Plot and the nmaplateplot R Package
Yanan Ren, et al.
April 7, 2026, Research Synthesis Methods
Reports
The Use of Real-World Data and Evidence in Clinical Trials
April 2026
Vaccines for Covid-19: Effectiveness and Value
April 7, 2026